China's Tianyin Pharmaceutical Receives Approval For Ofloxacin And Fleroxacin To Expand Antibiotic Product Line
This article was originally published in PharmAsia News
SHANGHAI - Tianyin Pharmaceutical, a Traditional Chinese Medicine and Western drug maker in China, announced it received manufacturing licenses from China's State FDA for its antibiotic products fluoroquinolone-based ofloxacin and quinolone broad-spectrum fleroxacin
You may also be interested in...
China Boosts Health System Reforms With Expanded National Drug Reimbursement List
BEIJING - In the government's latest move to expand coverage under sweeping health system reforms that are in the works China-wide, the Ministry of Human Resources and Social Security has added hundreds of new medicines to the latest edition of the national drug reimbursement catalog
Tianyin Completes Government Commission For Post-quake Medicines, Expects Expanded Revenue Despite Disruption In Operation
BEIJING - Tianyin Pharmaceutical recently completed a special government commission for traditional Chinese medicines and western drugs as part of a massive relief effort following a magnitude 7.9 earthquake that ripped through the western Chinese province of Sichuan in May
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).